Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Abstract Background Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R. This multicenter phase 1/2 study evaluated the maximum tolerated dose (MTD), safety, and clinical activity of pacritinib in patients with myelofibrosis (MF) and other adv...

Full description

Bibliographic Details
Main Authors: Srdan Verstovsek, Olatoyosi Odenike, Jack W. Singer, Tanya Granston, Suliman Al-Fayoumi, H. Joachim Deeg
Format: Article
Language:English
Published: BMC 2016-12-01
Series:Journal of Hematology & Oncology
Subjects:
FMS-like tyrosine kinase 3 inhibitors
Janus kinase 2 inhibitors
Myelofibrosis
Myeloid malignancies
Myelosuppression
Pacritinib
Online Access:http://link.springer.com/article/10.1186/s13045-016-0367-x

Internet

http://link.springer.com/article/10.1186/s13045-016-0367-x

Similar Items